Spindle Cell Sarcoma Treatment Market Research Report – Forecast to 2027

Spindle Cell Sarcoma Treatment Market Research Report: By Treatment (Radiotherapy, Chemotherapy, Cryotherapy, Surgical Removal (Conservative and Wide Surgical Removal Type), and Others) & by End-Users (Hospitals and Others) -Forecast Till 2027

ID: MRFR/Pharma/5005-HCR | | Region: Global | 90 Pages         

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Spindle Cell Sarcoma Treatment Market, by Treatment Type

6.1 Introduction

6.2 Surgical Removal

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.2.1 Conservative Surgical Removal Type

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.2.2 Wide Surgical Removal Type

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3 Cryotherapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.4 Radiotherapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.5 Hormone Therapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.6 Chemotherapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 7. Global Spindle Cell Sarcoma Treatment Market, by End-User

7.1 Introduction

7.2 Laboratories

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3 Hospitals

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.4 Clinics

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.5 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 8. Global Spindle Cell Sarcoma Treatment Market, by Region

8.1 Introduction

8.2 Americas

8.2.1 North America

8.2.1.1 US

8.2.1.2 Canada

8.2.2 South America

8.3 Europe

8.3.1 Western Europe

8.3.1.1 Germany

8.3.1.2 France

8.3.1.3 Italy

8.3.1.4 Spain

8.3.1.5 UK

8.3.1.6 Rest of Western Europe

8.3.2 Eastern Europe

8.4 Asia-Pacific

8.4.1 Japan

8.4.2 China

8.4.3 India

8.4.4 Australia

8.4.5 South Korea

8.4.6 Rest of Asia-Pacific

8.5 Middle East & Africa

8.5.1 Middle East

8.5.2 Africa

Chapter 9. Company Landscape

9.1 Introduction

9.2 Market Share Analysis

9.3 Key Development & Strategies

Chapter 10. Company Profiles

10.1 PharmaEngine, Inc

10.1.1 Company Overview

10.1.2 Product Overview

10.1.3 Financials Overview

10.1.4 Key Developments

10.1.5 SWOT Analysis

10.2 Morphotek Inc

10.2.1 Company Overview

10.2.2 Product Overview

10.2.3 Financial Overview

10.2.4 Key Developments

10.2.5 SWOT Analysis

10.3 Threshold Pharmaceutical

10.3.1 Company Overview

10.3.2 Product Overview

10.3.3 Financial Overview

10.3.4 Key Development

10.3.5 SWOT Analysis

10.4 Merck KGaA

10.4.1 Company Overview

10.4.2 Product Overview

10.4.3 Financial Overview

10.4.4 Key Development

10.4.5 SWOT Analysis

10.5 NantCell Inc

10.5.1 Company Overview

10.5.2 Product Overview

10.5.3 Financial overview

10.5.4 Key Developments

10.5.5 SWOT Analysis

10.6 NanoCarrier Co., Ltd

10.6.1 Company Overview

10.6.2 Product Overview

10.6.3 Financial Overview

10.6.4 Key Developments

10.6.5 SWOT Analysis

10.7 Athenex, Inc

10.7.1 Overview

10.7.2 Product Overview

10.7.3 Financial Overview

10.7.4 Key Developments

10.7.5 SWOT Analysis

Chapter 11 MRFR Conclusion

11.1 Key Findings

11.1.1 From CEO’s Viewpoint

11.1.2 Unmet Needs of the Market

11.2 Key Companies to Watch

11.3 Predictions for the Dental 3D Printing Industry

Chapter 12. Appendix

 

LIST OF TABLES

Table 1 Global Spindle Cell Sarcoma Treatment Market Synopsis, 2020–2027

Table 2 Global Spindle Cell Sarcoma Treatment Market Estimates and Forecast, 2020–2027

(USD Million)

Table 3 Global Spindle Cell Sarcoma Treatment Market, by Region, 2020–2027 (USD Million)

Table 4 Global Spindle Cell Sarcoma Treatment Market, by Treatment Type, 2020–2027 (USD Million)

Table 5 Global Spindle Cell Sarcoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 6 North America: Electron Microscopy Market, by Treatment Type, 2020–2027 (USD Million)

Table 7 North America: Spindle Cell Sarcoma Treatment by End-User, 2020–2027 (USD Million)

Table 8 US: Global Spindle Cell Sarcoma Treatment Market, by Treatment Type, 2020–2027 (USD Million)

Table 9 US: Spindle Cell Sarcoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 10 Canada: Spindle Cell Sarcoma Treatment Market, by Treatment Type, 2020–2027 (USD Million)

Table 11 Canada: Global Spindle Cell Sarcoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 12 South America: Global Spindle Cell Sarcoma Treatment Market, by Treatment Type, 2020–2027 (USD Million)

Table 13 South America: Global Spindle Cell Sarcoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 14 Europe: Global Spindle Cell Sarcoma Treatment Market, by Treatment Type, 2020–2027 (USD Million)

Table 15 Europe: Global Spindle Cell Sarcoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 16 Western Europe: Global Spindle Cell Sarcoma Treatment Market, by Treatment Type, 2020–2027 (USD Million)

Table 17 Western Europe: Global Spindle Cell Sarcoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 18 Eastern Europe: Global Spindle Cell Sarcoma Treatment Market, by Treatment Type, 2020–2027 (USD Million)

Table 19 Eastern Europe: Spindle Cell Sarcoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 20 Asia-Pacific: Global Spindle Cell Sarcoma Treatment Market, by Treatment Type, 2020–2027 (USD Million)

Table 21 Asia-Pacific: Global Spindle Cell Sarcoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 22 Middle East & Africa: Global Spindle Cell Sarcoma Treatment Market, by Treatment Type, 2020–2027 (USD Million)

Table 23 Middle East & Africa: Spindle Cell Sarcoma Treatment Market, by End-User, 2020–2027 (USD Million)

 


LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Spindle Cell Sarcoma Treatment Market

Figure 3 Segmentation Market Dynamics for Global Spindle Cell Sarcoma Treatment Market

Figure 4 Global Spindle Cell Sarcoma Treatment Market Share, by Treatment Type, 2020

Figure 5 Global Spindle Cell Sarcoma Treatment Market Share, by End-User, 2020

Figure 6 Global Spindle Cell Sarcoma Treatment Market Share, by Region, 2020

Figure 7 North America: Global Spindle Cell Sarcoma Treatment Share, by Country, 2020

Figure 8 Europe: Global Spindle Cell Sarcoma Treatment Share, by Country, 2020

Figure 9 Asia-Pacific: Global Spindle Cell Sarcoma Treatment Share, by Country, 2020

Figure 10 Middle East & Africa: Global Spindle Cell Sarcoma Treatment Share, by Country, 2020

Figure 11 Global Spindle Cell Sarcoma Treatment Share: Company Share Analysis, 2020 (%)

Figure 12 PharmaEngine, Inc: Key Financials

Figure 13 PharmaEngine, Inc: Segmental Revenue

Figure 14 PharmaEngine, Inc: Geographical Revenue

Figure 15 Morphotek Inc.: Key Financials

Figure 16 Morphotek Inc.: Segmental Revenue

Figure 17 Morphotek Inc.: Geographical Revenue

Figure 18 Threshold Pharmaceutical.: Key Financials

Figure 19 Threshold Pharmaceutical.: Segmental Revenue

Figure 20 Threshold Pharmaceutical.: Geographical Revenue

Figure 21 Merck KGaA: Key Financials

Figure 22 Merck KGaA: Segmental Revenue

Figure 23 Merck KGaA: Geographical Revenue

Figure 24 NantCell Inc: Key Financials

Figure 25 NantCell Inc: Segmental Revenue

Figure 26 NantCell Inc. Geographical Revenue

Figure 27 NanoCarrier Co., Ltd: Key Financials

Figure 28 NanoCarrier Co., Ltd: Segmental Revenue

Figure 29 NanoCarrier Co., Ltd: Geographical Revenue

Figure 30 Athenex, Inc: Key Financials

Figure 31 Athenex, Inc: Segmental Revenue

Figure 32 Athenex, Inc: Geographical Revenue


Spindle Cell Sarcoma Treatment Market

Spindle cell sarcoma treatment market is expected to grow at USD 1,405 million by 2027, at a CAGR 12.4% during the forecast period

Segmentation

By Treatment Radiotherapy Chemotherapy Cryotherapy Surgical Removal
By End-Users Hospitals And Others

Key Players

  • PharmaEngine
  • Morphotek Inc
  • Threshold Pharmaceutical
  • Merck KGaA
  • NantCell Inc
  • NanoCarrier Co.
  • Athenex

Drivers

  • production of new medicines
  • alternative treatment
  • conduction of awareness program by government
Speak to Analyst Request a Free Sample

Spindle Cell Sarcoma Treatment Market Overview
 
Spindle cell sarcoma treatment market is expected to register a CAGR ~6.1% during the forecast period Spindle cell sarcoma is an uncommon malignant tumor that can be established in bone or soft tissue. It can also arise in other body parts most typically in limbs (arms and legs). This form of tumor has no known etiology, but it can sometimes develop as a result of earlier radiotherapy treatment. Fever, weakness, anxiety, and confusion are all signs and symptoms of spindle cell sarcoma. Treatment with chemotherapy is the best strategy to cure and prevent the spindle cell sarcoma. Other variables, such as the development of new medicines, alternative treatments, and government-led public awareness campaigns, encourage the market to develop new therapies to treat spindle cell sarcoma.
 
Spindle cell sarcomas are treated with a variety of chemotherapeutic medicines, including dacarbazine, epirubicin, and others. In the projected term, the presence of a robust developmental pipeline is expected to accelerate market expansion. Similarly, the market for spindle cell sarcoma medications is expected to develop due to the increased adoption of innovative therapies and an increase in the prevalence of soft tissue sarcomas (STS). Furthermore, the market growth rate is expected to be fueled by significant technical advancements in treatment and diagnosis, as well as an increase in the incidence of sarcoma. Additionally, the government's increased awareness campaign to encourage the market to develop new treatments to treat spindle cell sarcoma is projected to have an impact on the global spindle cell sarcoma drugs market.

Segmentation


The spindle cell sarcoma treatment market has been segmented on the basis of types of treatment and end-user.


On the basis of types of treatment, the spindle cell sarcoma treatment market is segmented into surgical removal, cryotherapy, radiotherapy, hormone therapy, and chemotherapy. Surgical therapy is further sub-segmented into conservative surgical removal type and wide surgical removal type.


On the basis of end-user, the spindle cell sarcoma treatment market is segmented into hospital, clinics, and others.


Key players


Key players for the spindle cell sarcoma treatment market are PharmaEngine, Inc, Morphotek Inc, Threshold Pharmaceutical, Merck KGaA, NantCell Inc, NanoCarrier Co., Ltd, Athenex, Inc.


Regional Market Summary  


Spindle Cell Sarcoma Treatment Market Share (%), by Region, 2017


Spindle Cell Sarcoma Treatment Market Share


Source: Centers for Disease Control and Prevention (CDC)


On a regional basis, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.


Americas is likely to dominate the spindle cell sarcoma treatment market owing to the remarkable use of chemotherapy for the prevention of disease and favorable conditions for research and development.


According to a scientific report, of Surveillance, Epidemiology and End Results (SEER) database white people account for 79.1 % with spindle cell sarcoma cancer within the median age of 57 years.


Europe is the second largest market for the spindle cell sarcoma treatment followed by Asia-Pacific. Due to the availability of fund for research and development activity and growing emphasis on treating disease. Asia-Pacific shows the fastest growth in the market due to an increase in the prevalence of communicable disease. India and China are expected to be the fastest growing market for spindle cell sarcoma treatment.


The Middle East and Africa has the lowest market for spindle cell sarcoma treatment due to poor medical facilities and lack of technology.


Spindle Cell Sarcoma Treatment Market, by Types of Treatment



  • Radiotherapy

  • Chemotherapy

  • Hormone Therapy

  • Surgical Removal

  • Conservative Surgical Removal Type

  • Wide Surgical Removal Type

  • Cryotherapy


Spindle Cell Sarcoma Treatment Market, by End-User



  • Laboratories

  • Hospitals

  • Clinics

  • Others


Spindle Cell Sarcoma Treatment Market, by Region



  • Americas

    • North America

    • US

    • Canada

    • South America



  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe



  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • Republic of Korea

    • Rest of Asia-Pacific



  • Middle East & Africa

    • Middle East

    • Africa




Spindle Cell Sarcoma Treatment Market, by Key Players



  • PharmaEngine, Inc

  • Morphotek Inc

  • Threshold Pharmaceutical

  • Merck KGaA

  • NantCell Inc

  • NanoCarrier Co., Ltd

  • Athenex, Inc.


Recent Developmet


PharmaEngine, Inc. is a company in the market for sarcoma medications that are highly consolidated. In terms of market share, all of the companies are currently dominant including this.
 
Mid-size to smaller enterprises are projected to infiltrate the market by introducing new pharmaceuticals at lower prices, thanks to technology developments and product innovations. As a result, these newcomers are expected to have a significant future share including Morphotek Inc.

Intended Audience



  • Hospitals and clinics

  • Laboratories and associations



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   6.1% (2018-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Types of treatment and End-user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   PharmaEngine, Inc, Morphotek Inc, Threshold Pharmaceutical, Merck KGaA, NantCell Inc, NanoCarrier Co., Ltd, Athenex, Inc.
  Key Market Opportunities   key players in the market are engaged in new launches of chemotherapy drugs and strategic collaborations
  Key Market Drivers

  • Increase in aging population
  • Rising use of various treatment options to cure spindle cell sarcoma tumor
  • Increasing investment in research and development by government and non-government organization


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Spindle cell sarcoma treatment market CAGR would be 6.1% during the forecast period.

    Spindle cell sarcoma treatment market hurdles would be failure to follow distraction protocols and its adverse impact on the nerves.

    Spindle cell sarcoma treatment market has segments like hormone therapy, cryotherapy, surgical removal, radiotherapy, and chemotherapy.

    The Americas would ensure maximum growth for the spindle cell sarcoma treatment market.